Hikma Pharmaceuticals (HKMPF)
| Bid | 26.02 |
| Market Cap | 5.77B |
| Revenue (ttm) | 3.13B |
| Net Income (ttm) | 359M |
| EPS (ttm) | 1.61 |
| PE Ratio (ttm) | 16.27 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 27.57 |
| Volume | 10 |
| Avg. Volume (20D) | 237 |
| Open | 26.56 |
| Previous Close | 26.56 |
| Day's Range | 26.20 - 26.56 |
| 52-Week Range | 22.56 - 28.91 |
| Beta | 0.69 |
About HKMPF
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-in...
2 months ago · seekingalpha.com
Hikma Pharmaceuticals PLC (HKMPF) Q4 2024 Earnings Call Pre-Recorded (Transcript)Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q4 2024 Results Conference Call February 26, 2025 2:00 AM ET Company Participants Riad Mishlawi - Chief Executive Officer Khalid Nabilsi - Chief Financial Offic...
2 months ago · proactiveinvestors.co.uk
Hikma shares fall 5% as stock succumbs to profit taking after strong results and outlook statementHikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares fell five per cent in early trading as investors took profits despite the company reporting strong results and an upbeat outlook for 2025. Revenue...